How many clinical trials are tracked of rimegepant?

14 trials are tracked, 11 with published results.

Mode

All Infectious Disease Oncology Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Gastroenterology Primary Care & Family Medicine Nutrition & Obesity Medicine OB/GYN & Women's Health Orthopedics & Sports Medicine Genetics & Precision Medicine Radiology & Imaging Pulmonology & Critical Care Anesthesiology & Pain Medicine Physical Medicine & Rehab Nephrology Urology Hematology Dermatology Ophthalmology Emergency Medicine Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Questions

Text Size

rimegepant

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of rimegepant

14 trials tracked of rimegepant: 11 in phase 3 or 4 and 11 with published results. The most-cited published study has 396 citations.

14Trials tracked

11Phase 3 & 4

0Recruiting

11With published results

Phase distribution

Phase 4 4 Phase 3 7 Phase 2 2 Other / NA 1

Phase 3 Safety and Efficacy in Adult Subjects With Acute Migraines Completed · 396 cited
Phase 3 Trial in Adult Subjects With Acute Migraines Completed · 392 cited
Phase 3 Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults Completed · 350 cited
Phase 3 Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of Migraine Completed · 70 cited
Phase 3 Safety and Efficacy Study in Adult Subjects With Acute Migraines Completed · 50 cited
Phase 3 Open Label Safety Study in Acute Treatment of Migraine Completed · 44 cited

Show 8 more trials

Phase 4 A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine Completed · 43 cited
Phase 3 Efficacy and Safety Study of Rimegepant for Migraine Prevention in Japanese Subjects (Japan Only) Completed · 12 cited
Phase 4 Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications Completed · 5 cited
Phase 4 Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use Completed · 3 cited
Phase 4 Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention Completed · 2 cited
Phase 2 Rimegepant in Moderate Plaque-type Psoriasis Completed
Phase 2 Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine Completed
N/A Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey Completed

Showing the 14 most-cited and recently-updated of 14 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.